Media Releases › Arovella Therapeutics View All Arovella Therapeutics News SUDA Pharmaceuticals Appendix 4C for the consolidated Group for the final quarter of FY2019. 31 Jul 2019 01:19 PM SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the final quarter of FY2019. For more information, download the attached PDF. Download this document
